Literature DB >> 31450960

Loss in efficacy measures of tolfenamic acid in a tau knock-out model: Relevance to Alzheimer's disease.

Allison Leso1, Syed W Bihaqi2, Anwar Masoud3, Joanna K Chang4, Asma Lahouel5, Nasser Zawia1,2,4.   

Abstract

Entities:  

Keywords:  Alzheimer’s disease; neurodegeneration; specificity protein 1; tau; tolfenamic acid

Year:  2019        PMID： 31450960      PMCID： PMC6775567          DOI： 10.1177/1535370219871249

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN： 1535-3699


× No keyword cloud information.
  32 in total

1.  Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies.

Authors:  G Santpere; M Nieto; B Puig; I Ferrer
Journal:  Neurosci Lett       Date:  2005-12-27       Impact factor: 3.046

2.  The ability of tolfenamic acid to penetrate the brain: a model for testing the brain disposition of candidate Alzheimer's drugs using multiple platforms.

Authors:  Gehad M Subaiea; Bothaina H Alansi; David A Serra; Maged Alwan; Nasser H Zawia
Journal:  Curr Alzheimer Res       Date:  2011-12       Impact factor: 3.498

3.  Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.

Authors:  T Ishihara; B Zhang; M Higuchi; Y Yoshiyama; J Q Trojanowski; V M Lee
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.

Authors:  Eric T Larson; Kayode K Ojo; Ryan C Murphy; Steven M Johnson; Zhongsheng Zhang; Jessica E Kim; David J Leibly; Anna M W Fox; Molly C Reid; Edward J Dale; B Gayani K Perera; Jae Kim; Stephen N Hewitt; Wim G J Hol; Christophe L M J Verlinde; Erkang Fan; Wesley C Van Voorhis; Dustin J Maly; Ethan A Merritt
Journal:  J Med Chem       Date:  2012-03-13       Impact factor: 7.446

5.  Place navigation impaired in rats with hippocampal lesions.

Authors:  R G Morris; P Garrud; J N Rawlins; J O'Keefe
Journal:  Nature       Date:  1982-06-24       Impact factor: 49.962

6.  Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy.

Authors:  Joanna K Chang; Allison Leso; Gehad M Subaiea; Asma Lahouel; Anwar Masoud; Foqia Mushtaq; Reem Deeb; Aseel Eid; Miriam Dash; Syed W Bihaqi; Nasser H Zawia
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

7.  Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity.

Authors:  Kazuhito Tomizawa; Jun Ohta; Masayuki Matsushita; Akiyoshi Moriwaki; Sheng-Tian Li; Kohji Takei; Hideki Matsui
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

8.  Sp1 and Sp3 regulate transcription of the cyclin-dependent kinase 5 regulatory subunit 2 (p39) promoter in neuronal cells.

Authors:  Alvaro Valin; Julie D Cook; Sarah Ross; Christi L Saklad; Grace Gill
Journal:  Biochim Biophys Acta       Date:  2009-03

Review 9.  A clinical overview of cholinesterase inhibitors in Alzheimer's disease.

Authors:  Martin Farlow
Journal:  Int Psychogeriatr       Date:  2002       Impact factor: 3.878

10.  Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice.

Authors:  Gehad M Subaiea; Lina I Adwan; Aseef H Ahmed; Karen E Stevens; Nasser H Zawia
Journal:  Neurobiol Aging       Date:  2013-04-30       Impact factor: 4.673
View more
  1 in total

Review 1.  Fenamates as Potential Therapeutics for Neurodegenerative Disorders.

Authors:  Jaunetta Hill; Nasser H Zawia
Journal:  Cells       Date:  2021-03-22       Impact factor: 6.600
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.